Clinical Activity of L-Nmma Combined with Dometaxel in Chemorefractory MPBC Patients. Credit: Nature Communications (2024). Doi: 10.1038/s41467-024-54651-x
A National Study Seeking More Effective Treatment for Deadly Metaplastic Breast Cancer has identified two inhibitor drugs with the potential to interrupt Disease Progression.
Houston Methodist and a Team of Researchers from across the country examined the biology of metaplastic breast cancer, Comparing it to non-metaplastic triple negative breast cancer. They discovered Metaplastic Breast Cancers Typical Exhibit Two Unique Signaling Pathways in their Cell Interaction.
Researchers were abled to disrupt these pathways using a class of inhibitors typically used to treat advanced cancers – PHOSHOINOSITide 3 kinase inhibitor (P13k) ) Typically used to treat septic shock, cardiovascular disease and other conditions. When introduced to the cell, these drugs disrupted these pathways, making the treatment more effective.
A rare and aggressive form of disease, metaplastic breast cancer typically Grows faster and is more likely to metastasize or spread to other parts of the body than other general funds. It is also more likely to recude after successful initial treatment. Patients with Metaplastic Breast Cancer Will often receive However, Metaplastic Breast Cancer often does not respond well.
The findings are in the article, “nos inhibitizes metaplctive breast cancer to pi3k inhibition and taxane therapy via c-jun repression,” and Published in Nature CommunicationsThe Study’s Corresponding Author is Dr. Jenny Chang, The Executive Vice President, President and CEO, and Chief Academic Officer at the House Methodist Academic Institute. She Holds The Ernest Cockrell, JR. Presidential distinguished Chair at the Academic Institute and is Former Director of the Dr. Mary and Ron Neal Cancer Center at Houston Methodist.

EMT Reversal in MPBC Human Tumor Biopsies after l-nmma+taxane therapy. Credit: Nature Communications (2024). Doi: 10.1038/s41467-024-54651-x
“This is a significant finding trust it offers a promising therapeutic option for one of the most Aggressive and Difential-to-Treat Subypes of Breast Cancer,” Said Change. “We have the potential to improve outcomes for patients who currently face limited treatment options and poor programs, marking an important step forward in Cancer Research and Therapy.”
The First Author, Dr. Tejaswini Reddy, Hopes these Findings will help develop a specific care plan for metaplastic cancer patients and improve long-term survival of the disease.
“Our Findings Highlight a Promising Therapeutic Combination that could Hopesfully Change The Landscape of Metaplastic Breast Cancer Treat UICIAL to Improving Outcomes for Patients Facing this Rare and Aggressive Disease. Moreover, this Approach May have broader implications, potentially benefiting patients with other cancers with similar biology, “said reddy.
The findings of this preclinical study has translated into a Phase 2 Clinical Trial To help patients with this rare and agressive malignancy.
Chang’s collaborators on this study was: Tejaswini Reddy, Akshjot Puri, Liliana Guzman-RJAS, Christoforos Thomas, Wei Qian, Jhou, Hongo, Hong Zhao, Honor , Jose Thaiparambil, Roberto Rosato, Karina Ortega Martinez, Maria Florencia Chevaro, Camila Ayerbe, Noah Giese, David WINK, Stephen Locket, Stephen Wong, Jeffrey Chang, Savitri Krishna Yam, Clinton Yam, Clinton Yam A-Worms, and Funda Meric-Bernstam.
More information:
Tejaswini reddy et al, nos inhibitizes metaplctive breast cancer to pi3k inhibit and taxane therapy via c-jun repression, Nature Communications (2024). Doi: 10.1038/s41467-024-54651-x
Citation: A more effective treatment for aggressive breast cancer: two inhibitor drugs show potential (2025, February 3) retrieved 3 February 2025 from
This document is Subject to copyright. Apart from any Fair Dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
(Tagstotranslate) Medicine Research News (T) Medicine Research (T) Health Research News (T) Health Research (T) Health Science (T) Medicine Science